Fairvalue-Calculator Fairvalue-Calculator
EN DE

Ilex Medical Ltd (ILX) Fair Value & Analysis

Healthcare · Il · Market cap 547M ILA

Price47.37 ILA
Fair Value94.10 ILA
Upside+98.6%
Quality95/100
Evidence: High Range 64.08 ILA – 117.79 ILA

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Ilex Medical Ltd (ILX) currently trades at 47.37 ILA, while our model-based Fair Value estimate is 94.10 ILA — implying the stock looks roughly 98.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Ilex Medical Ltd engages in the import, marketing, distribution and sale of medical laboratory equipment and various diagnostic products, diagnostic systems, and kits and consumables in Israel, the United States, and internationally. The company also provides laboratory services, as well as is involved in the development, production, marketing and sale of software systems for information management in medical laboratories. Its products are used for performing tests in hospital medical laboratories, blood banks and health insurance funds, as well as for providing application and technical services to users. Ilex Medical Ltd was incorporated in 1990 and is based in Petah Tikva, Israel.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Ilex Medical Ltd (ILX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 94.10 ILA versus a price of 47.37 ILA — about +99% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ILX?
Our 21-model fair value for Ilex Medical Ltd is 94.10 ILA (as of Jun 25, 2026), built from audited fundamentals. The current price is 47.37 ILA.
What is the quality score of ILX?
Ilex Medical Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.